Namenda (Memantine), Alzheimer's medication
Namenda (Memantine)is a medication used in the treatment of Alzheimer's. ... Renal Impairment: Memantine pharmacokinetics were evaluated following single ...
Memantine - Pubdrug
16.3 Pharmacokinetics Articles. 16.4 Drug Interaction Articles ... Memantine exhibits linear pharmacokinetics over the entire the dosage range of 10-40 mg/day. ...
07-FRL-0654 Namenda v5
Memantine is well absorbed after oral administration and has linear pharmacokinetics over ... Renal Impairment: Memantine pharmacokinetics were evaluated ...
PATIENT INSTRUCTIONS FOR NAMENDA
Renal Impairment: Memantine pharmacokinetics were evaluated follow ... the pharmacokinetics of memantine, metformin and glyburide. ...
Namenda (Memantine HCL) Drug Information: Uses, Side Effects, Drug ...
... the prescription medication Namenda (Memantine HCL), drug uses, dosage, side ... Renal Impairment: Memantine pharmacokinetics were evaluated following single ...
NAMENDAВ® TABLETS (memantine hydrochloride) Rx Only DESCRIPTION NAMENDA ...
Renal Impairment: Memantine pharmacokinetics were evaluated following single ... pharmacokinetics of memantine in patients with hepatic impairment have not been ...
memantine : Complexes, Storage & Clinical Research on Healthline.com
Memantine reduces the actions of chemicals in the brain that may contribute to the ... No effect on pharmacokinetics of memantine, metformin, or glyburide with ...
Approval Labeling Text NDA 21-487 Page 1 R
Pharmacokinetics. Memantine is well absorbed after oral administration and has linear ... The pharmacokinetics of memantine in patients ...
Namenda Official FDA information, side effects and uses.
Accurate, FDA approved Namenda information for healthcare professionals and ... Renal Impairment: Memantine pharmacokinetics were evaluated following single ...
Memantine (28:92) - 303043
... population.2 5 7 15 Memantine pharmacokinetics were similar in elderly patients ... affect the pharmacokinetics of memantine, metformin, or glyburide, and the ...
|
Pharmacokinetic study of memantine in healthy and renally impaired subjectsObjective: Our objective was to evaluate the pharmacokinetics of the Alzheimer's disease treatment memantine in subjects with normal and impaired renal function. Methods: This was a single-center, single-dose, open-label study. Thirty-two subjects aged 18 to 80 years were assigned to 1 of 4 groups (8 subjects each) based on baseline creatinine clearance: normal renal function ( 80 mL/min), mild renal impairment (50-80 mL/min), moderate renal impairment (30-49 mL/min), and severe renal impairment (5-29 mL/min). A single 20-mg memantine dose was administered under fasting conditions. Assessments included pharmacokinetic and safety measures. Results: Thirty-one subjects completed the study. There were no relevant differences in maximum memantine plasma concentration between subjects with normal and impaired renal function of any severity.